Render Target: STATIC
Render Timestamp: 2024-11-21T13:41:13.005Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:23:31.831
Product last modified at: 2024-08-30T22:45:07.809Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Rosiglitazone Maleate #78946

    Product Information

    Product Usage Information

    Rosiglitazone Maleate is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.06 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at room tempertaure, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 473.5 g/mol
    Purity >98%
    Molecular Formula C18H19N3O3S • C4H4O4
    CAS 155141-29-0
    Solubility Soluble in DMSO at 3 mg/mL or DMF at 10 mg/mL.

    Background

    Rosiglitazone Maleate is an agonist of peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated nuclear receptor preferentially expressed in adipocytes, vascular smooth muscle cells, and macrophages. Rosiglitazone Maleate mediates adipogenesis, lipid metabolism, and insulin sensitivity (1). Rosiglitazone Maleate binds both PPARγ1 and PPARγ2 isoforms with high affinity. Treatment of mesenchymal stem cells with Rosiglitazone Maleate resulted in adipocyte differentiation (2). The treatment of type 2 diabetes mellitus using Rosiglitazone Maleate is controversial as its use can lead to serious side effects, including myocardial hypertrophy and heart failure (3). Exposure of murine neuroblastoma cells and primary hippocampal neurons to Rosiglitazone Maleate protected these cells from oxidative stress. Rosiglitazone Maleate binding to PPARγ activated transcription of neurotrophic factor-α1 (NF-α1), which promoted increased expression of BCL-2 and inhibition of caspase-3 (4). Studies suggest that Rosiglitazone Maleate prevents microglial activation, promotes microglial anti-inflammatory polarization, and suppresses inflammatory cytokines in inflammation-related diseases. In a mouse model of status epilepticus, Rosiglitazone Maleate prevented microglial activation and inhibited pilocarpine-induced status epilepticus (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.